IOO: a novel assay to predict patient response to immune checkpoint inhibitors,...
IOO: a novel assay to predict patient response to immune checkpoint inhibitors, optimising patient stratification to these therapies and tripling solid tumour patient outcomes in immuno-onco
Immunotherapy is a beacon of hope in cancer's battle, but with a 10-20% response rate in solid tumors, its potential is untapped. Predicting patient responses to treatment, which current methods are ill-equipped for, is an urgent...
ver más
¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video
Proyectos interesantes
RARITY
RAtional design of canceR ImmunoTherapY one size does not f...
1M€
Cerrado
ImmunoChip
Nano-assisted digitalizing of cancer phenotyping for immunot...
2M€
Cerrado
EXPAND IT
EXPANDing Immune Cells and their Tumor Antigens during check...
3M€
Cerrado
GLIOMATCH
The malignant Glioma immuno-oncology matchmaker: towards dat...
11M€
Cerrado
NANODIAGNOSTIC
Super-resolution microscopy for immune checkpoint inhibitors...
150K€
Cerrado
RTI2018-098682-B-I00
APRENDIZAJE PROFUNDO ESPACIO-TEMPORAL PARA LA PREDICION DE R...
140K€
Cerrado
Información proyecto IOO - Improving IO
Duración del proyecto: 26 meses
Fecha Inicio: 2024-05-06
Fecha Fin: 2026-07-31
Líder del proyecto
FASTBASE SOLUTIONS
El desarrollo, asesoramiento y comercializacion de productos y servicios para la investigacion
TRL
4-5
| 1M€
Presupuesto del proyecto
4M€
Fecha límite de participación
Sin fecha límite de participación.
Descripción del proyecto
Immunotherapy is a beacon of hope in cancer's battle, but with a 10-20% response rate in solid tumors, its potential is untapped. Predicting patient responses to treatment, which current methods are ill-equipped for, is an urgent unmet medical need. Our project stands for industrializing our analytically validated multiplexed protein-function based biomarker assay (IOO), currently TRL6, which is based on our proprietary bio-imaging technology. Whilst scientifically validated, we need further clinical validation to obtain increased datasets required for regulatory certification for clinical deployment. This assay could triple the efficacy of currently available immune-oncology treatments by accurately predicting patient response to immune checkpoint inhibitors - the basis of 90% of current immuno-oncology therapies. If successful, we will bring this transformative solution to hospitals worldwide. The upshot could be game-changing: doubling survival rates for high-prevalence, lethal tumors like lung cancer.